Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Bevacizumab + Paclitaxel + Pembrolizumab |
| Indication/Tumor Type | ovary epithelial cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | ovary epithelial cancer | sensitive | Bevacizumab + Paclitaxel + Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (ENGOT-ov65/KEYNOTE-B96) that supported FDA approval, Keytruda (pembrolizumab) plus Taxol (paclitaxel), with or without Avastin (bevacizumab), significantly improved progression-free survival (8.3 vs 7.2 mo, HR 0.72, p=0.0014) and overall survival (18.2 vs 14.0 mo, HR 0.76, p=0.0053) in patients with CD274 (PD-L1)-positive (CPS>/=1) platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (Annals of Oncology, Volume 36, S1582; NCT05116189). | detail... detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Keytruda (pembrolizumab) FDA Drug Label | Full reference... | |
| LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study | Full reference... |